Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study

Study limitation reported by the research below: “Ustekinumab is not FDA-approved specifically for UC in the same manner as for Crohn's disease; its use in this context may reflect off-label or region-specific prescribing practices.”